Developability considerations for bispecific and multispecific antibodies
Bispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of candidate developability enables demotion of...
Saved in:
| Main Authors: | Alaa Amash, Gesa Volkers, Patrick Farber, Daniel Griffin, K. Shawn Davison, Allison Goodman, Raffi Tonikian, Aaron Yamniuk, Bryan Barnhart, Tim Jacobs |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2394229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01) -
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01) -
Current advances in bispecific T cell–engaging therapies
by: Emmanuel Owusu Ansah, et al.
Published: (2025-04-01) -
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer
by: S. M. Greiner, et al.
Published: (2025-07-01) -
The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma
by: Xiaoling Zhou, et al.
Published: (2025-08-01)